Table 1. Patient and tumor characteristics at baseline.
| Characteristics | No. (%), N = 50s |
|---|---|
| Sex | |
| Male | 42 (84) |
| Female | 8 (16) |
| Age (years) | |
| <60 | 40 (80) |
| ≥60 | 10 (20) |
| Etiology of liver disease | |
| HBV | 48 (96) |
| Other | 2 (4) |
| ECOG performance status | |
| 0 | 30 (60) |
| 1 | 20 (40) |
| Child-Pugh class | |
| A | 40 (80) |
| B | 10 (20) |
| Serum α-FP (ng/mL) | |
| <400 | 32 (64) |
| ≥400 | 18 (36) |
| Portal vein invasion | |
| Present | 12 (24) |
| Absent | 38 (76) |
| Distal metastasis | |
| Present | 26 (52) |
| Absent | 24 (48) |
| Metastasis site* | |
| Lung | 18 (36) |
| Bone | 6 (12) |
| Abdomen | 2 (4) |
| Thoracic wall | 2 (4) |
| BCLC stage | |
| B | 12 (24) |
| C | 38 (76) |
| Previous treatment** | |
| None | 8 (16) |
| Surgery | 36 (72) |
| RFA | 16 (32) |
| TACE | 13 (26) |
| α-FP (ng/mL) | 7134 (1.7–58 344) |
AST, aspartate aminotransferase; BCLC, Barcelona Clinic Liver Cancer; ECOG, Eastern Cooperative Oncology Group; HBV, hepatitis B virus; RFA, radiofrequency ablation; TACE, transcatheter arterial chemoembolization; α-FP, alpha-fetoprotein.
*Three patients had 2 metastatic sites.
**Sixteen patients received ≥2 types of previous treatment.